89 related articles for article (PubMed ID: 12761741)
1. Small molecules as inhibitors of cyclin-dependent kinases.
Huwe A; Mazitschek R; Giannis A
Angew Chem Int Ed Engl; 2003 May; 42(19):2122-38. PubMed ID: 12761741
[TBL] [Abstract][Full Text] [Related]
2. ATP-noncompetitive inhibitors of CDK-cyclin complexes.
Orzáez M; Gortat A; Mondragón L; Bachs O; Pérez-Payá E
ChemMedChem; 2009 Jan; 4(1):19-24. PubMed ID: 19039815
[TBL] [Abstract][Full Text] [Related]
3. Recent advances and new directions in the discovery and development of cyclin-dependent kinase inhibitors.
Fischer PM
Curr Opin Drug Discov Devel; 2001 Sep; 4(5):623-34. PubMed ID: 12825457
[TBL] [Abstract][Full Text] [Related]
4. Specific inhibition of cyclin-dependent kinases and cell proliferation by harmine.
Song Y; Kesuma D; Wang J; Deng Y; Duan J; Wang JH; Qi RZ
Biochem Biophys Res Commun; 2004 Apr; 317(1):128-32. PubMed ID: 15047157
[TBL] [Abstract][Full Text] [Related]
5. Cyclin-dependent kinase inhibitors.
Fischer PM; Endicott J; Meijer L
Prog Cell Cycle Res; 2003; 5():235-48. PubMed ID: 14593718
[TBL] [Abstract][Full Text] [Related]
6. Progress in the evaluation of CDK inhibitors as anti-tumor agents.
McInnes C
Drug Discov Today; 2008 Oct; 13(19-20):875-81. PubMed ID: 18639646
[TBL] [Abstract][Full Text] [Related]
7. Cell-cycle molecules in mesothelioma: an overview.
Spugnini EP; Campioni M; D'Avino A; Caruso G; Citro G; Baldi A
J Exp Clin Cancer Res; 2007 Dec; 26(4):443-9. PubMed ID: 18365537
[TBL] [Abstract][Full Text] [Related]
8. The cell cycle, cyclin-dependent kinases, and viral infections: new horizons and unexpected connections.
Schang LM
Prog Cell Cycle Res; 2003; 5():103-24. PubMed ID: 14593705
[TBL] [Abstract][Full Text] [Related]
9. Designing inhibitors of cyclin-dependent kinases.
Hardcastle IR; Golding BT; Griffin RJ
Annu Rev Pharmacol Toxicol; 2002; 42():325-48. PubMed ID: 11807175
[TBL] [Abstract][Full Text] [Related]
10. Control of vascular cell proliferation and migration by cyclin-dependent kinase signalling: new perspectives and therapeutic potential.
Andrés V
Cardiovasc Res; 2004 Jul; 63(1):11-21. PubMed ID: 15194457
[TBL] [Abstract][Full Text] [Related]
11. Small-molecule cyclin-dependent kinase modulators.
Senderowicz AM
Oncogene; 2003 Sep; 22(42):6609-20. PubMed ID: 14528286
[TBL] [Abstract][Full Text] [Related]
12. A three-dimensional in silico pharmacophore model for inhibition of Plasmodium falciparum cyclin-dependent kinases and discovery of different classes of novel Pfmrk specific inhibitors.
Bhattacharjee AK; Geyer JA; Woodard CL; Kathcart AK; Nichols DA; Prigge ST; Li Z; Mott BT; Waters NC
J Med Chem; 2004 Oct; 47(22):5418-26. PubMed ID: 15481979
[TBL] [Abstract][Full Text] [Related]
13. Cyclins and related kinases in cancer cells.
Malumbres M
J BUON; 2007 Sep; 12 Suppl 1():S45-52. PubMed ID: 17935277
[TBL] [Abstract][Full Text] [Related]
14. A proteome-wide CDK/CRK-specific kinase inhibitor promotes tumor cell death in the absence of cell cycle progression.
Caligiuri M; Becker F; Murthi K; Kaplan F; Dedier S; Kaufmann C; Machl A; Zybarth G; Richard J; Bockovich N; Kluge A; Kley N
Chem Biol; 2005 Oct; 12(10):1103-15. PubMed ID: 16242653
[TBL] [Abstract][Full Text] [Related]
15. Cyclin-dependent kinases: bridging their structure and function through computations.
De Vivo M; Bottegoni G; Berteotti A; Recanatini M; Gervasio FL; Cavalli A
Future Med Chem; 2011 Sep; 3(12):1551-9. PubMed ID: 21882947
[TBL] [Abstract][Full Text] [Related]
16. CDK inhibitors in cancer therapy: what is next?
Malumbres M; Pevarello P; Barbacid M; Bischoff JR
Trends Pharmacol Sci; 2008 Jan; 29(1):16-21. PubMed ID: 18054800
[TBL] [Abstract][Full Text] [Related]
17. Structure-based discovery and optimization of potential cancer therapeutics targeting the cell cycle.
Thomas MP; McInnes C
IDrugs; 2006 Apr; 9(4):273-8. PubMed ID: 16596481
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of neuronal apoptosis by the cyclin-dependent kinase inhibitor GW8510: identification of 3' substituted indolones as a scaffold for the development of neuroprotective drugs.
Johnson K; Liu L; Majdzadeh N; Chavez C; Chin PC; Morrison B; Wang L; Park J; Chugh P; Chen HM; D'Mello SR
J Neurochem; 2005 May; 93(3):538-48. PubMed ID: 15836613
[TBL] [Abstract][Full Text] [Related]
19. Imidazoles: SAR and development of a potent class of cyclin-dependent kinase inhibitors.
Anderson M; Andrews DM; Barker AJ; Brassington CA; Breed J; Byth KF; Culshaw JD; Finlay MR; Fisher E; McMiken HH; Green CP; Heaton DW; Nash IA; Newcombe NJ; Oakes SE; Pauptit RA; Roberts A; Stanway JJ; Thomas AP; Tucker JA; Walker M; Weir HM
Bioorg Med Chem Lett; 2008 Oct; 18(20):5487-92. PubMed ID: 18815031
[TBL] [Abstract][Full Text] [Related]
20. Silymarin and silibinin cause G1 and G2-M cell cycle arrest via distinct circuitries in human prostate cancer PC3 cells: a comparison of flavanone silibinin with flavanolignan mixture silymarin.
Deep G; Singh RP; Agarwal C; Kroll DJ; Agarwal R
Oncogene; 2006 Feb; 25(7):1053-69. PubMed ID: 16205633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
